Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in Boston, Massachusetts, and three research facilities, i…
An institutional-grade, numbers-driven thesis on VRTX — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of August 8, 2026, TradersQuant's model rates Vertex Pharmaceuticals Inc (VRTX) 63/100 with a 12-month base-case forecast of $614.72 — +23.9% versus the current price of $496.07. Vertex Pharmaceuticals Inc trades at $496.07 in the Biotechnology sector, with a market capitalisation of $121.09B. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month TradersQuant model price target for VRTX is $614.72, implying +23.9% versus the current price. The model's 12-month scenario range runs from $587.48 (bear) to $680.94 (bull), with a base case of $614.72.
On the fundamentals, Vertex Pharmaceuticals shows a P/E of 28.3, trailing revenue of $12.52B, revenue growth of +10.2% YoY. This page also tracks VRTX's short interest, institutional (smart-money) positioning and the options market — the same cross-signal view institutions watch.
VRTX currently carries a TradersQuant composite score of 63/100, which we read as a neutral-to-watch signal. The Wall-Street analyst consensus is "buy". Our 12-month price target of $614.72 implies +23.9% from $496.07. This is research, not financial advice — always combine it with your own judgement.
The TradersQuant 12-month model price target for VRTX is $614.72, about +23.9% versus the latest price of $496.07. Consensus is based on 37 analysts.
TradersQuant's 12-month model forecast for VRTX is a base case of $614.72, ranging from $587.48 (bear) to $680.94 (bull), an expected return of +23.9%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for VRTX over the next 12 months is $614.72 in the base case (bear $587.48, bull $680.94), versus today's price of $496.07. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for VRTX — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates VRTX's fair value at $653.32, implying +31.7% of expected upside versus the current price.
Vertex Pharmaceuticals does not currently pay a dividend.
Data and model outputs are for research only and are not financial advice. Figures update continuously.
